Skip to main content
SpringerLink
Log in

71/m in reduziertem Allgemeinzustand mit Sklerenikterus

Vorbereitung auf die Facharztprüfung: Fall 19

71/m—Reduced general condition and scleral jaundice

Preparation for the medical specialist examination: part 19

  • Facharzt-Training
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Ducreux M et al (2015) Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Gastrointest Cancers. https://doi.org/10.1093/annonc/mdv295

    Article  Google Scholar 

  2. Vincent A et al (2011) Pancreatic cancer. Lancet 378(9791):607–620. https://doi.org/10.1016/S0140-6736(10)62307-0

    Article  PubMed  PubMed Central  Google Scholar 

  3. Park HS et al (2016) Prognostic scoring index for patients with metastatic pancreatic adenocarcinoma. Cancer Res Treat 48(4):1253–1263. https://doi.org/10.4143/crt.2015.400

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tong H, Fan Z, Liu B, Lu T (2018) The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep 8(1):8666. https://doi.org/10.1038/s41598-018-26811-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Conroy T et al (2018) FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New Engl J Med 379(25)2395–2406. https://doi.org/10.1056/NEJMoa1809775

    Article  CAS  Google Scholar 

  6. Conroy T et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825. https://doi.org/10.1056/NEJMoa1011923

    Article  CAS  PubMed  Google Scholar 

  7. Von Hoff DD et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369

    Article  CAS  Google Scholar 

  8. Imaoka H et al (2016) Evaluation of modified glasgow prognostic score for pancreatic cancer: a retrospective cohort study. Pancreas 45(2):211–217. https://doi.org/10.1097/MPA.0000000000000446

    Article  PubMed  Google Scholar 

  9. Pelzer U et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5‑fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47(11):1676–1681. https://doi.org/10.1016/j.ejca.2011.04.011

    Article  CAS  Google Scholar 

  10. Wang-Gillam A et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387(10018):545–557. https://doi.org/10.1016/S0140-6736(15)00986-1

    Article  CAS  PubMed  Google Scholar 

  11. Onkopedia (2018) Onkopedia Leitlinie – Pankreaskarzinom. https://www.onkopedia.com/de/onkopedia/guidelines/pankreaskarzinom/@@guideline/html/index.html#litID0E6RAG. Zugegriffen: 4. Aug. 2021

  12. Hasan S et al (2019) Advances in pancreatic cancer biomarkers. Oncol Rev 13(1):410. https://doi.org/10.4081/oncol.2019.410

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Berardi RMA et al (2013) Prognostic factors in pancreatic cancer: the role of perineural, vascular and lymphatic invasion and of Ca19‑9. J Gastrointest Dig Syst 2013:3

    Google Scholar 

  14. Golan T et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317–327

    Article  CAS  Google Scholar 

  15. Boulay BR (2012) Biliary stents for pancreas cancer with obstruction: the problem with plastic. J Gastrointest Oncol 3(4):306–308. https://doi.org/10.3978/j.issn.2078-6891.2012.047

  16. Campello E et al (2019) The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. Br J Cancer 121:359–371. https://doi.org/10.1038/s41416-019-0510-x

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pelzer U et al (2015) Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 33(18):2028–2034. https://doi.org/10.1200/JCO.2014.55.1481

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Onkologie und Hämatologie und Knochenmarktransplantation mit Abteilung für Pneumologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland

    M. Schönrock &  M. Sinn

Authors
  1. M. Schönrock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Sinn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Sinn.

Ethics declarations

Interessenkonflikt

M. Schönrock gibt an, dass kein Interessenkonflikt besteht. M. Sinn erhielt Honorare für Advisory Boards von AstraZeneca, Amgen, Servier, MSD, Sanofi; Honorare für Vorträge von BMS, Incyte, Pfizer, Servier; im Rahmen von Forschungsprojekten von AstraZeneca, Bayer, BMS, MSD, Roche, Servier, Amgen, Incyte, Pierre Fabre (Institution).

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.

The supplement containing this article is not sponsored by industry.

Additional information

Redaktion

M. Christopeit, Tübingen

C. Oing, Hamburg

K. Höffken, Düsseldorf

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schönrock, M., Sinn, M. 71/m in reduziertem Allgemeinzustand mit Sklerenikterus. Onkologe 27 (Suppl 1), 109–113 (2021). https://doi.org/10.1007/s00761-021-01022-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-021-01022-6

Schlüsselwörter

Search

Navigation